Top

Endocrine

Published in:

01-02-2018 | Research Letter

Pasireotide versus pituitary surgery: a retrospective analysis of 12 months of treatment in patients with Cushing’s disease

Authors: Valentina Guarnotta, Alessandro Ciresi, Maria Pitrone, Giuseppe Pizzolanti, Carla Giordano

Published in: Endocrine | Issue 2/2018

Excerpt

Pituitary surgery represents the first-line treatment for most patients with Cushing’s disease (CD) [1, 2]. …

B.M. Biller, A.B. Grossman, P.M. Stewart, S. Melmed, X. Bertagna, J. Bertherat, M. Buchfelder, A. Colao, A.R. Hermus, L.J. Hofland, A. Klibanski, A. Lacroix, J.R. Lindsay, J. Newell-Price, L.K. Nieman, S. Petersenn, N. Sonino, G.K. Stella, B. Swearingen, M.L. Vance, J.A. Wass, M. Boscaro, Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement. J. Clin. Endocrinol. Metab. 93, 2454–2462 (2008)CrossRefPubMedPubMedCentral

K.I. Alexandraki, G.A. Kaltsas, A.M. Isidori, H.L. Storr, F. Afshar, I. Sabin, S.A. Akker, S.L. Chew, W.M. Drake, J.P. Monson, G.M. Besser, A.B. Grossman, Long-term remission and recurrence rates in Cushing’s disease: predictive factors in a single-centre study. Eur. J. Endocrinol. 168, 639–648 (2013)CrossRefPubMed

R.M. Starke, D.L. Reames, C.J. Chen, E.R. Laws, J.A. Jane Jr., Endoscopic transsphenoidal surgery for Cushing disease: techniques, outcomes, and predictors of remission. Neurosurgery 72, 240–247 (2013)CrossRefPubMed

L.K. Nieman, B.M. Biller, J.W. Findling, M.H. Murad, J. Newell-Price, M.O. Savage, A. Tabarin, Treatment of Cushing’s syndrome: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 100, 2807–2831 (2015)CrossRefPubMedPubMedCentral

R. Pivonello, M. De Leo, A. Cozzolino, A. Colao, The treatment of Cushing’s disease. Endocr. Rev. 36, 385–486 (2015)CrossRefPubMedPubMedCentral

M. Boscaro, W.H. Ludlam, B. Atkinson, J.E. Glusman, S. Petersenn, M. Reincke, P. Snyder, A. Tabarin, B.M. Biller, J. Findling, S. Melmed, C.H. Darby, K. Hu, Y. Wang, P.U. Freda, A.B. Grossman, L.A. Frohman, J. Bertherat, Treatment of pituitary-dependent Cushing’s disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J. Clin. Endocrinol. Metab. 94, 115–122 (2009)CrossRefPubMed

A. Colao, S. Petersenn, J. Newell-Price, J.W. Findling, F. Gu, M. Maldonado, U. Schoenherr, D. Mills, L.R. Salgado, B.M. Biller, Pasireotide B2305 study group. A 12-month phase 3 study of pasireotide in Cushing’s disease. N. Engl. J. Med. 366, 914–924 (2012)CrossRefPubMed

R. Pivonello, S. Petersenn, J. Newell-Price, J.W. Findling, F. Gu, M. Maldonado, A. Trovato, G. Hughes, L.R. Salgado, A. Lacroix, J. Schopohl, B.M. Biller, Pasireotide B2305 study group. Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing’s disease: results from a phase III study. Clin. Endocrinol. (Oxf). 81, 408–417 (2014)CrossRefPubMed

J. Schopohl, F. Gu, R. Rubens, L. Van Gaal, J. Bertherat, M. Ligueros-Saylan, A. Trovato, G. Hughes, L.R. Salgado, M. Boscaro, R. Pivonello, Pasireotide B2305 Study Group. Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing’s disease: results from an open-ended, open-label extension trial. Pituitary 18, 604–612 (2015)CrossRefPubMed

10.

D.R. Matthews, J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, R.C. Turner, Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 28, 412–419 (1985)CrossRefPubMed

11.

M. Matsuda, R. DeFronzo, Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycaemic insulin clamp. Diabetes Care 22, 1462–1470 (1999)CrossRefPubMed

12.

K.M. Utzschneider, R.L. Prigeon, M.V. Faulenbach, J. Tong, D.B. Carr, E.J. Boyko, D.L. Leonetti, M.J. McNeely, W.Y. Fujimoto, S.E. Kahn, Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. Diabetes Care 32, 335–341 (2009)CrossRefPubMedPubMedCentral

13.

R.R. Henry, T.P. Ciaraldi, D. Armstrong, P. Burke, M. Ligueros-Saylan, S. Mudaliar, Hyperglycaemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J. Clin. Endocrinol. Metab. 98, 3446–3453 (2013)CrossRefPubMed

14.

C. Giordano, V. Guarnotta, R. Pivonello, M.C. Amato, C. Simeoli, A. Ciresi, A. Cozzolino, A. Colao, Is diabetes in Cushing’s syndrome only a consequence of hypercortisolism? Eur. J. Endocrinol. 170, 311–319 (2013)CrossRefPubMed

15.

V. Guarnotta, M.C. Amato, R. Pivonello, G. Arnaldi, A. Ciresi, L. Trementino, R. Citarrella, D. Iacuaniello, G. Michetti, C. Simeoli, A. Colao, C. Giordano, The degree of urinary hypercortisolism is not correlated with the severity of cushing’s syndrome. Endocrine 10, 1–9 (2016)

16.

P.P. Toth, Insulin resistance, small LDL particles, and risk for atherosclerotic disease. Curr. Vasc. Pharmacol. 12, 653–657 (2014)CrossRefPubMed

17.

B. Van Zaane, E. Nur, A. Squizzato, O.M. Dekkers, M.T. Twickler, E. Fliers, V.E. Gerdes, H.R. Büller, D.P. Brandjes, Hypercoagulable state in Cushing’s syndrome: a systematic review. J. Clin. Endocrinol. Metab. 94, 2743–2750 (2009)CrossRefPubMed

18.

R. van der Pas, C. de Bruin, F.W. Leebeek, M.P. de Maat, D.C. Rijken, A.M. Pereira, J.A. Romijn, R.T. Netea-Maier, A.R. Hermus, P.M. Zelissen, F.H. de Jong, A.J. van der Lely, W.W. de Herder, S.W. Lamberts, L.J. Hofland, R.A. Feelders, The hypercoagulable state in Cushing’s disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy. J. Clin. Endocrinol. Metab. 97, 1303–1310 (2012)CrossRefPubMed

19.

M.C. Amato, V. Guarnotta, C. Giordano, Body composition assessment for the definition of cardiometabolic risk. J. Endocrinol. Invest. 36, 537–543 (2013)PubMed

Title: Pasireotide versus pituitary surgery: a retrospective analysis of 12 months of treatment in patients with Cushing’s disease
Authors: Valentina Guarnotta
Alessandro Ciresi
Maria Pitrone
Giuseppe Pizzolanti
Carla Giordano
Publication date: 01-02-2018
Publisher: Springer US
Published in: Endocrine / Issue 2/2018
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-017-1276-7

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Pasireotide versus pituitary surgery: a retrospective analysis of 12 months of treatment in patients with Cushing’s disease

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2018

The tear cytokine profile in patients with active Graves’ orbitopathy

Prevalence of morphometric vertebral fractures in “difficult” patients with acromegaly with different biochemical outcomes after multimodal treatment

MEN1 in children and adolescents: Data from patients of a regional referral center for hereditary endocrine tumors

Effects of chronic endurance exercise training on serum 25(OH)D concentrations in elderly Japanese men

Skeletal fragility induced by overtreatment of adrenal insufficiency

Clinical profile of juvenile primary hyperparathyroidism: a prospective study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page